Hypertension, Resistant to Conventional Therapy Clinical Trial
Official title:
Renal Sympathetic Denervation for Treatment Resistant Hypertension and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (The Re-Shape CV-Risk Study)
The Re-Shape CV-Risk Study is a clinical study where renal adrenergic denervation (RDN) is
done in high risk patients with treatment-resistant hypertension. RDN is a mini-invasive,
percutaneous technique where an ablation catheter is inserted through a femoral artery into
the renal arteries, for destruction of the adrenergic nerve bundles in the artery adventitia
by means of radio-frequency ablation. RDN leads to sympathetic denervation of the kidneys,
which in the "Symplicity trials" led to an impressive reduction of blood pressure (- 33 /-11
mmHg). In a pilot study, where 40 % of the patients had diabetes, RDN seemed to have
beneficial effects not only on blood pressure, but also on insulin sensitivity and
hyperinsulinaemia.
The investigators aim to introduce RDN as a clinical study where blood pressure reduction
and methodical, technical aspects will be evaluated, but more importantly, also additional
effects of RDN on sub-clinical organ damage (endothelial function, vascular stiffness,
fundus-, heart-, kidney injury), quality of life, arrhythmia, and glucose metabolism. The
investigators hypothesis is that RDN will have positive effect on glucose metabolism, QOL
and sub-clinical organ damage.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02385864 -
CPAP Effect on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension
|
N/A | |
| Completed |
NCT01833429 -
Autonomic Dysfunction in Resistant Hypertension
|
N/A | |
| Completed |
NCT02426099 -
Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension
|
Phase 4 | |
| Recruiting |
NCT02623036 -
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors
|
Phase 1 | |
| Completed |
NCT02587533 -
Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation
|
N/A | |
| Recruiting |
NCT01863082 -
Resistant Hypertension and Physical Activity Performed in a Heated Pool
|
N/A | |
| Terminated |
NCT03730519 -
UK Registry for Baroreflex Activation Therapy
|
N/A | |
| Active, not recruiting |
NCT05017935 -
RADIANCE Continued Access Protocol
|
N/A | |
| Completed |
NCT01520506 -
Rapid Renal Sympathetic Denervation for Resistant Hypertension
|
N/A | |
| Active, not recruiting |
NCT02369081 -
Optimum Treatment for Drug-Resistant Hypertension
|
Phase 4 | |
| Withdrawn |
NCT04542681 -
MANP in African Americans With Hypertension
|
Phase 1 | |
| Completed |
NCT05395403 -
Use of Automated Office Blood Pressure Monitoring
|
N/A | |
| Recruiting |
NCT02057783 -
Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension
|
N/A | |
| Completed |
NCT01848275 -
Full Length Versus Proximal Renal Arteries Ablation
|
N/A | |
| Completed |
NCT01062763 -
The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
|
Phase 3 | |
| Completed |
NCT01834118 -
Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension
|
N/A | |
| Active, not recruiting |
NCT01703780 -
The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis
|
N/A | |
| Not yet recruiting |
NCT02042066 -
Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension
|
Phase 1 | |
| Completed |
NCT02667912 -
Distal Renal Denervation
|
N/A | |
| Recruiting |
NCT00994617 -
Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
|
Phase 4 |